AFT Pharmaceuticals (AFT): Maxigesic Rapid US Tablet Approval
AFT Pharmaceuticals (AFT) has today announced US FDA approval of its rapid release tablet form of Maxigesic, which is step one in the process for...
276 Views
AFT Pharmaceuticals: 1H23 Result — A Few Sniffles
AFT Pharmaceuticals' (AFT) 1H23 result highlighted ongoing strong underlying revenue momentum which was ahead of our expectations, but this was...
285 Views
AFT Pharmaceuticals (AFT): 1H23 Result – Initial Impressions
AFT Pharmaceuticals (AFT) reported a below expectations 1H23 result with EBIT ex licensing income (underlying EBIT) of NZ$3.4m versus our NZ$5.0m...
275 Views
AFT Pharmaceuticals: A Picture of Health; OUTPERFORM
We initiate full coverage of AFT Pharmaceuticals (AFT) with a 12 month target price of NZ$5.00 and an OUTPERFORM rating; we think the market under...
133 Views
AFT Pharmaceuticals: 1H22 Result — A Bump in the Road
AFT Pharmaceuticals1H22 Result — A Bump in the Road RESEARCH INSIGHTS AFT Pharmaceuticals (AFT) reported a lower than expected underlying 1H22...
802 Views